High sensitivity measurement of CRP and disease progression in multiple sclerosis.
The authors measured serum C-reactive protein (CRP) serially in patients with multiple sclerosis (MS) who participated the PRISMS study using a high-sensitivity technique. CRP values were similar in patients with MS and in healthy controls but higher during MS relapses than in remission (p = 0.010). CRP levels were lower during treatment with high-dose interferon beta 1a than placebo (p = 0.035) and higher during first 12 months of study in patients who progressed by year 4 compared with stable patients (p = 0.007).
Soilu-Hänninen
M
M
Department of Neurology, Institute of Biomedicine, University of Turku, Finland. mersoi@utu.fi
Koskinen
J O
JO
Laaksonen
M
M
Hänninen
A
A
Lilius
E-M
EM
Waris
M
M
D000328:Adult; D001681:Biological Assay / Q000379:methods; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis / Q000378:metabolism*; D002490:Central Nervous System / Q000378:metabolism / Q000503:physiopathology; D004185:Disability Evaluation; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D011237:Predictive Value of Tests; D055502:Secondary Prevention; D016896:Treatment Outcome
D015415:Biomarkers; D016899:Interferon-beta; D002097:C-Reactive Protein; D000068556:Interferon beta-1a